According to Invitrogen, Dynabeads SSEA-4 addresses a key challenge in translational research by separating undifferentiated stem cells from those that are differentiated.
Scientists from Invitrogen and the Buck Institute for Age Research have collaborated in developing this solution that depletes greater than 99% of undifferentiated human embryonic stem cells from differentiated populations, the company said.
Paul Pickering, general manager of Invitrogen cell therapy systems business at Life Technologies, said: “Dynabeads SSEA-4 is an innovative and highly effective solution that addresses one of the key challenges in the development of safer stem cell therapies. It was made possible through the collaboration of several technologies and business groups from different parts of the company coming together to offer a single solution to a problem faced by many of our stem cell customers.”